Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy

Pharmacogenetics and Genomics

Volumn 17, Issue 9, 2007, Pages 755-764

  Arnedo, Mireia ^a   Taffé, Patrick ^b   Sahli, Roland ^a   Furrer, Hansjakob ^c   Hirschel, Bernard ^d   Elzi, Luigia ^e   Weber, Rainer ^f   Vernazza, Pietro ^g   Bernasconi, Enos ^h   Darioli, Roger ⁱ   Bergmann, Sven ^a   Beckmann, Jacques S ^a,j   Telenti, Amalio ^a,j   Tarr, Philip E ^j,p   Bachmann, S ^p   Battegay, M ^p   Bernasconi, E ^p   Bucher, H ^p   Burgisser P ^p   Cattacin, S ^p   Cavassini, M ^p   Egger, M ^p   Erb, P ^p   Fierz, W ^p   Fischer, M ^p   Flepp, M ^p   Fontana, A ^p   Francioli, P ^k   Furrer, H ^l   Gorgievski, M ^p   Gunthard H ^p   Hirschel, B ^p   Kaiser, L ^p   Kind, C ^p   Klimkait, T ^p   Ledergerber, B ^p   Lauper, U ^p   Opravil, M ^p   Paccaud, F ^p   Pantaleo, G ^p   Perrin, L ^p   Piffaretti, J C ^p   Rickenbach, M ^m   Rudin, C ⁿ   Schupbach J ^p   Speck, R ^p   Telenti, A ^p   Trkola, A ^p   Vernazza, P ^o   Weber, R ^p   Yerly, S ^p   more..

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b Swiss HIV Cohort Study Data Center   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^h Ospedale Civico Lugano   (Switzerland)

ⁱ UNIVERSITY OF LAUSANNE   (Switzerland)

^j LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^k SHCS   (Switzerland)

^l Clinical and Laboratory Committee

^m Data Center

ⁿ Mother and Child Substudy

^o Scientific Board

^p Scientific Board ^*

more..

Author keywords

Antiretroviral therapy; Dyslipidemia; HIV; Metabolic complications; Pharmacogenetics; Single nucleotide polymorphism

Indexed keywords

ABC TRANSPORTER A1; ANTIRETROVIRUS AGENT; APOLIPOPROTEIN A; APOLIPOPROTEIN E; ATAZANAVIR; BETA 2 ADRENERGIC RECEPTOR; CHOLESTEROL ESTER TRANSFER PROTEIN; EFAVIRENZ; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPASE C; LIPASE G; LIPID; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN APOA5; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL LIPASE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; GENETIC VARIABILITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HYPERTRIGLYCERIDEMIA; LIPID TRANSPORT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34547917168     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32814db8b7     Document Type: Article

References (46)

1. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352:48-62.
2. Dube MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003; 37:613-627.
3. Manuel O, Thiebaut R, Darioli R, Tarr PE. Treatment of dyslipidaemia in HIV-infected persons. Expert Opin Pharmacother 2005; 6:1619-1645.
4. Friis-Moller N, Sabin CA,Weber R, d'Arminio MA, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
5. Friis-Moller N, Reiss P, El-Sadr W, D'Arminio Monforte A, Thiebaut R, De Wit S, et al. Exposure to PI and NNRTI and risk of myocardial infarction: results from the D:A:D study. Program and Abstracts of the 12th Conference on Retroviruses and Opportunistic Infections, Denver, 5-8 February 2006 (abstract No. 144).
6. Fontas E, van LF, Sabin CA, Friis-Moller N, Rickenbach M, d'Arminio MA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004; 189:1056-1074.
7. Periard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999; 100:700-705.
8. Doser N, Sudre P, Telenti A, Wietlisbach V, Nicod P, Darioli R, et al. Persistent dyslipidemia in HIV-infected individuals switched from a protease inhibitor-containing to an efavirenz-containing regimen. J Acquir Immune Defic Syndr 2001; 26:389-390.
9. Martinez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003; 349:1036-1046.
10. Young J,Weber R, Rickenbach M, Furrer H, Bernasconi E, Hirschel B, et al. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antivir Ther 2005; 10:585-591.
11. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
12. van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004; 1:e19.
13. Tarr PE, Taffe P, Bleiber G, Furrer H, Rotger M, Martinez R, et al. Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J Infect Dis 2005; 191:1419-1426.
14. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-2099.
15. Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005; 19:153-162.
16. Fellay J, Boubaker K, Ledergerber B, Bernasconi E, Furrer H, Battegay M, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001; 358:1322-1327.
17. Freimer NB, Sabatti C. Guidelines for association studies in Human Molecular Genetics. Hum Mol Genet 2005; 14:2481-2483.
18. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-265.
19. Diggle PJ. An approach to the analysis of repeated measurements. Biometrics 1988; 44:959-971.
20. Diggle PJ, Heagerty P, Liang KY, Zeger S. Analysis of longitudinal data. 2nd edition. Oxford: Oxford University Press; 2002.
21. Laird NM, Donnelly C, Ware JH. Longitudinal studies with continuous responses. Stat Meth Med Res 1992; 1:225-247.
22. Jones RH, Boadi-Boateng F. Unequally spaced longitudinal data with AR(1) serial correlation. Biometrics 1991; 47:161-175.
23. Chi EM, Reinsel G. Model for longitudinal data with random effects and AR(1) errors. J Am Stat Societ 1989; 84:452-459.
24. Diggle PJ, Verbyla AP. Nonparametric estimation of covariance structure in longitudinal data. Biometrics 1998; 54:401-415.
25. Purnell JQ, Zambon A, Knopp RH, Pizzuti DJ, Achari R, Leonard JM, et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000; 14:51-57.
26. Ware JH, Dockery DW, Louis TA, Xu XP, Ferris BG Jr, Speizer FE. Longitudinal and cross-sectional estimates of pulmonary function decline in never-smoking adults. Am J Epidemiol 1990; 132:685-700.
27. Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol 1999; 28:964-974.
28. Zucchini W. An introduction to model selection. J Math Psychol 2000; 44:41-61.
29. Murtaugh PA. Methods of variable selection in regression modelling. Commun Statist: Simul Comput 1998; 27:711-734.
30. Saville DJ. Multiple comparison procedures: the practical solution. Am Statist 1990; 44:174-180.
31. Roback PJ, Askins RA. Judicious use of multiple hypothesis tests. Conserv Biol 2003; 19:261-267.
32. Chunrong AI, Norton EC. Interaction terms in logit and probit models. Econ Lett 2003; 80:123-129.
33. Starr JR, McKnight B. Assessing interaction in case-control studies: type I errors when using both additive and multiplicative scales. Epidemiology 2004; 15:422-427.
34. Timm NH, Wiesner AJ. Model selection and prediction in multiple linear regression. Unpublished report ftp://ftp.pitt.edu/users/t/i/timm/Publications/ Linpapr.PDF. 2006.
35. Fauvel J, Bonnet E, Ruidavets JB, Ferrieres J, Toffoletti A, Massip P, et al. An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. AIDS 2001; 15:2397-2406.
36. Pennacchio LA, Olivier M, Hubacek JA, Krauss RM, Rubin EM, Cohen JC. Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum Mol Genet 2002; 11:3031-3038.
37. Talmud PJ, Hawe E, Martin S, Olivier M, Miller GJ, Rubin EM, et al. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet 2002; 11:3039-3046.
38. Dachet C, Poirier O, Cambien F, Chapman J, Rouis M. New functional promoter polymorphism, CETP/-629, in cholesteryl ester transfer protein (CETP) gene related to CETP mass and high density lipoprotein cholesterol levels: role of Sp1/Sp3 in transcriptional regulation. Arterioscler Thromb Vasc Biol 2000; 20:507-515.
39. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet 2001; 29:306-309.
40. Colhoun HM, McKeigue PM, Davey SG. Problems of reporting genetic associations with complex outcomes. Lancet 2003; 361:865-872.
41. Foulkes AS, Wohl DA, Frank I, Puleo E, Restine S, Wolfe ML, et al. Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy. PLoS Med 2006; 3:e52.
42. Han Z, Heath SC, Shmulewitz D, Li W, Auerbach SB, Blundell ML, et al. Candidate genes involved in cardiovascular risk factors by a family-based association study on the island of Kosrae, Federated States of Micronesia. Am J Med Genet 2002; 110:234-242.
43. Rodondi N, Darioli R, Ramelet AA, Hohl D, Lenain V, Perdrix J, et al. High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis retinoic acid therapy for acne: a pharmacogenetic study. Ann Intern Med 2002; 136:582-589.
44. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 2002; 31:33-36.
45. Janssens AC, Pardo MC, Steyerberg EW, van Duijn CM. Revisiting the clinical validity of multiplex genetic testing in complex diseases. Am J Hum Genet 2004; 74:585-588.
46. Weedon MN, McCarthy MI, Hitman G, Walker M, Groves CJ, Zeggini E, et al. Combining information from common type 2 diabetes risk polymorphisms improves disease prediction. PLoS Med 2006; 3:e374.